Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Agios Pharmaceuticals, Inc. (AGIO)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
28.99-0.63 (-2.13%)
At close: 04:00PM EDT
29.30 +0.31 (+1.07%)
After hours: 05:25PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close29.62
Open29.34
Bid21.60 x 800
Ask45.95 x 900
Day's Range27.90 - 29.35
52 Week Range16.75 - 50.98
Volume608,993
Avg. Volume747,423
Market Cap1.574B
Beta (5Y Monthly)1.34
PE Ratio (TTM)1.26
EPS (TTM)22.93
Earnings DateApr 27, 2022 - May 02, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est34.00
  • GlobeNewswire

    Agios Appoints Cecilia Jones as Chief Financial Officer

    Cecilia Jones Cecilia Jones, CFO of Agios Pharmaceuticals CAMBRIDGE, Mass., Sept. 19, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare and genetically defined diseases, today announced the appointment of Cecilia Jones to the role of chief financial officer, effective Sept. 26, 2022. Ms. Jones will replace Jonathan Biller, who served as the company’s previous chief financial officer and head of corporat

  • GlobeNewswire

    Agios Receives Positive CHMP Opinion for PYRUKYND® (mitapivat) for the Treatment of Pyruvate Kinase (PK) Deficiency in Adult Patients

    – Agios Expects a Decision on the Marketing Authorization Application by the European Commission within 67 Days of the Adoption of the Positive CHMP Opinion –CAMBRIDGE, Mass., Sept. 16, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare and genetically defined diseases, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive

  • TheStreet.com

    A Technical Strategy to 'Buy' Agios Pharmaceuticals

    Agios Pharmaceuticals is pioneering therapies for genetically defined diseases, with a near-term focus on developing therapies for hemolytic anemias (a blood condition that occurs when your red blood cells are destroyed faster than they can be replaced). In this daily bar chart we can see a price decline to a June low followed by a rally above the 50-day moving average line and the slower-to-react 200-day line. The On-Balance-Volume (OBV) line shows a decline into a June low followed by a rising pattern telling us that AGIO traders have shifted from aggressive sellers to aggressive buyers.

Advertisement
Advertisement